Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CARBOPLATIN\PACLITAXEL Cause Malignant neoplasm progression? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with CARBOPLATIN\PACLITAXEL. This represents 6.8% of all adverse event reports for CARBOPLATIN\PACLITAXEL.

5
Reports of Malignant neoplasm progression with CARBOPLATIN\PACLITAXEL
6.8%
of all CARBOPLATIN\PACLITAXEL reports
0
Deaths
1
Hospitalizations

How Dangerous Is Malignant neoplasm progression From CARBOPLATIN\PACLITAXEL?

Of the 5 reports, 1 (20.0%) required hospitalization.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CARBOPLATIN\PACLITAXEL. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does CARBOPLATIN\PACLITAXEL Cause?

Neuropathy peripheral (6) Drug ineffective (5) Fatigue (5) Nausea (5) Off label use (5) Product use in unapproved indication (5)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Related Pages

CARBOPLATIN\PACLITAXEL Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression CARBOPLATIN\PACLITAXEL Demographics